FCM
BIIB icon

Fieldview Capital Management’s Biogen BIIB Stock Holding History

Fieldview Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Buy
17,659
+3,387
+24% +$624K 0.95% 3
2025
Q4 		$2.51M Buy
+14,272
New +$2.33M 0.43% 72
2025
Q3 		– Sell
-8,837
Closed -$1.11M – 398
2025
Q2 		$1.11M Buy
+8,837
New +$1.1M 0.17% 176

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fieldview Capital Management's BIIB Position: Q1 2026 in Review

Fieldview Capital Management increased its Biogen (BIIB) stake by 24% in Q1 2026, buying an estimated $624K and bringing the position to 17,659 shares worth $3.24M. The position accounts for 0.95% of the portfolio, ranked #3.

Fieldview Capital Management first reported a position in BIIB in Q2 2025 and has held it in 3 quarters since. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Fieldview Capital Management held 17,659 shares of Biogen worth $3.24M as of Q1 2026.
  • Fieldview Capital Management bought 3,387 Biogen shares in Q1 2026, an estimated $624K.
  • Biogen made up 0.95% of Fieldview Capital Management's portfolio in Q1 2026, its #3 holding.
  • Fieldview Capital Management first reported a position in Biogen in Q2 2025 and has held it in 3 quarters since.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Fieldview Capital Management's 13F filing for Q1 2026, filed 14 May 2026.